Azafaros
- Biotech or pharma, therapeutic R&D
Azafaros B.V. is a clinical-stage biotechnology company founded in 2018, dedicated to developing disease-modifying therapies for rare genetic metabolic disorders, particularly lysosomal storage diseases (LSDs) such as GM1 and GM2 gangliosidoses and Niemann-Pick disease type C (NPC). The company's lead candidate, nizubaglustat, is an orally available, brain-penetrant small molecule with a unique dual mode of action, currently advancing into Phase 3 clinical trials.
Azafaros originated from scientific discoveries at Leiden University and Amsterdam UMC and is supported by a team of seasoned industry professionals. The company is backed by leading investors, including Jeito Capital, Forbion Growth, Seroba, Pictet Group and a syndicate of leading Dutch and Swiss existing investors including Forbion Ventures, BioGeneration Ventures (BGV), BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital.
Address
BaselBasel-Stadt
Switzerland
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}